These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 8045754

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63. [Our experience with "supertransfusive" treatment of homozygous beta-thalassemia].
    Esposito L, Ferrara M, Ponte G.
    Pediatria (Napoli); 1983; 91(1):27-30. PubMed ID: 6889088
    [No Abstract] [Full Text] [Related]

  • 64. Epidemiological situation and treatment of patients with thalassemia major in Germany: results of the German multicenter beta-thalassemia study.
    Cario H, Stahnke K, Sander S, Kohne E.
    Ann Hematol; 2000 Jan; 79(1):7-12. PubMed ID: 10663615
    [Abstract] [Full Text] [Related]

  • 65. Psychosocial implications of Thalassemia Major.
    Aydinok Y, Erermis S, Bukusoglu N, Yilmaz D, Solak U.
    Pediatr Int; 2005 Feb; 47(1):84-9. PubMed ID: 15693873
    [Abstract] [Full Text] [Related]

  • 66. Deferoxamine in thalassemia major.
    Lucarelli G, Clift R, Angelucci E.
    N Engl J Med; 1995 Jan 26; 332(4):271; author reply 272-3. PubMed ID: 7808502
    [No Abstract] [Full Text] [Related]

  • 67. Can deferoxamine be considered an ototoxic drug?
    Masala W, Meloni F, Gallisai D, Careddu M, Secchi G, Cuccuru GB, Loriga V, Salvo G.
    Scand Audiol Suppl; 1988 Jan 26; 30():237-8. PubMed ID: 3227279
    [Abstract] [Full Text] [Related]

  • 68. Evaluation of a new method of administration of the iron chelating agent deferoxamine.
    Borgna-Pignatti C, Cohen A.
    J Pediatr; 1997 Jan 26; 130(1):86-8. PubMed ID: 9003855
    [Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70. [Evaluation of the compliance of thalassemic patients at a structured ambulatory day hospital].
    Maj M, Magni LA, Confalonieri C.
    Pediatr Med Chir; 1995 Jan 26; 17(1):49-51. PubMed ID: 7739927
    [Abstract] [Full Text] [Related]

  • 71. Deferoxamine in thalassemia major.
    Splendiani G, Tozzo C, Mazzarella V, Casciani CU.
    N Engl J Med; 1995 Jan 26; 332(4):270-1. PubMed ID: 7808501
    [No Abstract] [Full Text] [Related]

  • 72. Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity.
    Bentur Y, Koren G, Tesoro A, Carley H, Olivieri N, Freedman MH.
    Clin Pharmacol Ther; 1990 Apr 26; 47(4):478-82. PubMed ID: 2328556
    [Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions.
    Freedman MH, Grisaru D, Olivieri N, MacLusky I, Thorner PS.
    Am J Dis Child; 1990 May 26; 144(5):565-9. PubMed ID: 2330923
    [Abstract] [Full Text] [Related]

  • 75. [Current treatment of thalassemia major in children].
    Lévy G, Bost M.
    Pediatrie; 1980 May 26; 35(5):451-5. PubMed ID: 7422454
    [No Abstract] [Full Text] [Related]

  • 76. Platyspondyly in treated beta-thalassemia.
    Orzincolo C, Castaldi G, Scutellari PN.
    Eur J Radiol; 1994 May 26; 18(2):129-33. PubMed ID: 8055985
    [Abstract] [Full Text] [Related]

  • 77. Current growth patterns in children and adolescents with thalassemia major.
    Origa R, Danjou F, Orecchia V, Zappu A, Dessì C, Foschini ML, Leoni GB, Moi P, Morittu M, Demurtas A, Loche S.
    Blood; 2016 Nov 24; 128(21):2580-2582. PubMed ID: 27737888
    [No Abstract] [Full Text] [Related]

  • 78. Impact of psychosocial status and disease knowledge on deferoxamine adherence among thalassaemia major adolescents.
    Al-Kloub MI, Salameh TN, Froelicher ES.
    Int J Nurs Pract; 2014 Jun 24; 20(3):265-74. PubMed ID: 24888999
    [Abstract] [Full Text] [Related]

  • 79. Frequency of sensory neural hearing loss in major Beta-thalassemias in southern iran.
    Faramarzi A, Karimi M, Heydari ST, Shishegar M, Kaviani M.
    Iran J Pediatr; 2010 Sep 24; 20(3):308-12. PubMed ID: 23056722
    [Abstract] [Full Text] [Related]

  • 80. Case report 744. Deferoxamine-induced skeletal dysplasia.
    Borenstein ZC, Hyman CB, Rimoin DL, Chapman CL, Lachman R.
    Skeletal Radiol; 1992 Sep 24; 21(8):534-7. PubMed ID: 1465648
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.